Get the Stockscreener App
10.17
1.90%
0.19
After Hours:
10.17
Iteos Therapeutics Inc stock is traded at $10.17, with a volume of 1.11M.
It is up +1.90% in the last 24 hours and up +29.55% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$9.98
Open:
$10
24h Volume:
1.11M
Relative Volume:
0.92
Market Cap:
$389.24M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-3.2286
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+0.00%
1M Performance:
+29.55%
6M Performance:
+32.42%
1Y Performance:
-37.61%
1-Day Range:
$9.96
$10.19
1-Week Range:
$9.93
$10.19
52-Week Range:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.17 | 389.24M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
ITeos Therapeutics Insider Sold Shares Worth $1,048,264, According to a Recent SEC Filing - marketscreener.com
Bank of America Corp DE Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) PT at $15.86 - Defense World
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
ITeos Therapeutics Insider Sold Shares Worth $1,592,520, According to a Recent SEC Filing - marketscreener.com
Director David Hallal Sells 114,682 Shares of ITeos Therapeutics Inc (ITOS) - GuruFocus
Squarepoint Ops LLC Sells 18,686 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics CEO Michel Detheux sells $1.59m in stock By Investing.com - Investing.com India
iTeos Therapeutics CEO Michel Detheux sells $1.59m in stock - Investing.com
iTeos Therapeutics Executives Sell Significant Shares - TradingView
Nuveen Asset Management LLC Trims Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iteos therapeutics announces board resignation - Investing.com
iteos therapeutics announces board resignation By Investing.com - Investing.com UK
Tim Van Hauwermeiren Resigns from iTeos Board - TipRanks
Deutsche Bank AG Sells 14,418 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
More bad news in biotech: Watertown cancer firm iTeos shutting down - The Boston Globe
Long Term Trading Analysis for (ITOS) - news.stocktradersdaily.com
Q2 EPS Forecast for iTeos Therapeutics Decreased by Analyst - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Position Increased by Ameriprise Financial Inc. - Defense World
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know - MSN
Wedbush Lowers Earnings Estimates for iTeos Therapeutics - Defense World
Rx Rundown: Novartis, iTeos Therapeutics, Moderna and more - Medical Marketing and Media
iTeos Therapeutics Stock Jumps Following Operational Closure Announcement - MSN
All Over For iTeos But Applause For Plan To Return Cash Fast - insights.citeline.com
iTeos to shut down operations after TIGIT setback and GSK exit - The Pharma Letter
iTeos Therapeutics (NASDAQ:ITOS) Receives “Equal Weight” Rating from Wells Fargo & Company - Defense World
iTeos Therapeutics to wind down operations, explore asset sales By Investing.com - Investing.com South Africa
iTeos Therapeutics (NASDAQ:ITOS) Lowered to “Neutral” Rating by Wedbush - Defense World
Wedbush cuts iTeos stock rating, raises PT to $12 from $10 - Investing.com Canada
Drug developer iTeos to shut down operations after cancer therapy setback - 1470 & 100.3 WMBD
Cancer drugmaker iTeos to shut down - BioPharma Dive
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’ - Investing.com India
iTeos Therapeutics stock surges on wind-down news By Investing.com - Investing.com Canada
Watertown immuno-oncology biotech winds down operations - The Business Journals
iTeos Therapeutics (ITOS) Downgraded by Wells Fargo with Revised Price Target | ITOS Stock News - GuruFocus
iTeos Therapeutics (ITOS) Faces Downgrade Amid Operational Changes | ITOS Stock News - GuruFocus
ITeos Therapeutics (ITOS) Sees Downgrade and Target Price Cut | - GuruFocus
ITeos Therapeutics (ITOS) Sees Downgrade and Target Price Cut | ITOS Stock News - GuruFocus
iTeos Therapeutics stock surges on wind-down news - Investing.com
ITeos Therapeutics (ITOS) Receives Analyst Downgrade from Wedbus - GuruFocus
iTeos Therapeutics (ITOS) Downgraded as Company Plans Operationa - GuruFocus
Wedbush Downgrades iTeos Therapeutics (ITOS) Rating to Neutral | - GuruFocus
I Teos Therapeutics Inc Expected Severance Costs Of $21.8 Million To $24.7 Million - marketscreener.com
ITeos Therapeutics (ITOS) Receives Analyst Downgrade from Wedbush | ITOS Stock News - GuruFocus
Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10 - marketscreener.com
iTeos Therapeutics (ITOS) to Cease Operations and Explore Strate - GuruFocus
iTeos Therapeutics (ITOS) Shares Surge on Plans to Cease Operati - GuruFocus
iTeos Therapeutics (ITOS) to Wind Down Operations, Focus on Shar - GuruFocus
Drug developer iTeos winds down after cancer therapy setback - marketscreener.com
iTeos Therapeutics (ITOS) to Wind Down Operations, Focus on Shareholder Value | ITOS Stock News - GuruFocus
iTeos Therapeutics Announces Strategic Wind Down Plan - TipRanks
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iteos Therapeutics Inc Stock (ITOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Option Exercise |
4.30 |
43,882 |
188,693 |
43,882 |
| Detheux Michel | Chief Executive Officer |
Jun 10 '25 |
Option Exercise |
4.30 |
26,400 |
113,520 |
153,903 |
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Option Exercise |
4.30 |
8,400 |
36,120 |
144,303 |
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Sale |
10.03 |
43,882 |
440,136 |
0 |
| Detheux Michel | Chief Executive Officer |
Jun 10 '25 |
Sale |
10.02 |
43,883 |
439,708 |
0 |
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Sale |
10.03 |
8,400 |
84,252 |
135,903 |
| Detheux Michel | Chief Executive Officer |
Jun 10 '25 |
Sale |
10.02 |
8,400 |
84,168 |
135,903 |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):